Christopher Tehlirian

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

Seth Forman, David M. Pariser, Yves Poulin et al. · Journal of Investigative Dermatology · 2020 · 105 citations

Medicine, Pharmacology, Pharmacotherapy +14

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study

Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan et al. · Journal of the American Academy of Dermatology · 2022 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

High-dose cyclophosphamide without stem cell rescue in scleroderma

Christopher Tehlirian, Laura K. Hummers, Barbara White et al. · Annals of the Rheumatic Diseases · 2007 · 35 citations

Medicine, Clinical Sciences, Pharmacotherapy +13

Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

Christopher Tehlirian, Elena Peeva, Elizabeth Kieras et al. · The Lancet Rheumatology · 2020 · 32 citations

Medicine, Pharmacokinetics, Pharmacology +10

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Ravi Shankar Prasad Singh, Vivek Pradhan, Erika Roberts et al. · Clinical and Translational Science · 2020 · 27 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15